Journal
CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 14, Issue 2, Pages 94-101Publisher
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-012-0767-5
Keywords
Tyrosine kinase inhibitors; Drug interactions; CYP; Pharmacokinetic; Pharmacodynamic
Categories
Funding
- MSD Oncology
Ask authors/readers for more resources
The adverse effects associated to traditional chemotherapy are well known and broadly studied. In the recent years several tyrosine kinase inhibitors have been approved for cancer treatment and numerous are under investigation. These drugs target specific mutated/over-expressed tyrosin kinase receptors and frecuently their pharmacokinetic/pharmacodinamic behavior is not fully elucidated. These new drugs may interact with non-antineoplastic drugs leading to undesirable adverse effects. In this article, we will discuss different types of drug interactions and briefly review the pharmacokinetics and mechanisms of action of tyrosine kinase inhibitors in clinical use, with a particular emphasis on the risk of the occurrence of such interactions based on currently available scientific evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available